Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 6 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 2 |
| HIV/AIDS Therapeutics Market to 2018 - Introduction | 11 | 1 |
| HIV/AIDS Therapeutics Market to 2018 - Overview | 12 | 19 |
| Disease Overview | 12 | 1 |
| Diagnostic Tests for HIV | 13 | 1 |
| Antibody Test | 13 | 1 |
| Polymerase Chain Reaction Test | 13 | 1 |
| Home HIV Test | 13 | 1 |
| WHO Guidelines for HIV/AIDS Treatment | 14 | 1 |
| WHO Clinical Staging of HIV Disease in Adults and Adolescents | 15 | 1 |
| Summary of Changes to the WHO s Guidelines on Initiation of ART based on CD4 Count and Clinical Staging | 16 | 1 |
| Summary of Changes to WHO s Guidelines on First-line Antiretrovirals | 17 | 1 |
| Summary of Changes to the WHO s Guidelines on Second-line Antiretrovirals | 18 | 1 |
| Drugs Classes Used in HIV/AIDS Treatment | 19 | 1 |
| Nucleoside/Nucleotide Reverse Transcriptase Inhibitors | 19 | 1 |
| Non-nucleoside Reverse Transcriptase Inhibitors | 20 | 1 |
| Protease Inhibitors | 20 | 1 |
| Fusion Inhibitors | 21 | 1 |
| CCR5 Co-receptor Antagonist | 21 | 1 |
| Integrase Inhibitors | 21 | 1 |
| Multi-class Combination Drugs | 22 | 1 |
| Key Marketed Products | 23 | 1 |
| Atripla | 23 | 1 |
| Overview | 23 | 1 |
| Efficacy | 23 | 1 |
| Safety | 23 | 1 |
| Clinical Study Details | 24 | 1 |
| Truvada | 25 | 1 |
| Overview | 25 | 1 |
| Efficacy | 25 | 1 |
| Safety | 25 | 1 |
| Clinical Study Details | 25 | 2 |
| Reyataz | 27 | 1 |
| Overview | 27 | 1 |
| Efficacy | 27 | 1 |
| Safety | 27 | 1 |
| Clinical Study Details | 27 | 1 |
| Sustiva | 28 | 1 |
| Overview | 28 | 1 |
| Efficacy | 28 | 1 |
| Safety | 28 | 1 |
| Clinical Study Details | 28 | 1 |
| Isentress | 29 | 1 |
| Overview | 29 | 1 |
| Efficacy | 29 | 1 |
| Safety | 29 | 1 |
| Clinical Study Details | 29 | 1 |
| Advancements in HIV/AIDS Vaccine Research | 30 | 1 |
| HIV/AIDS Therapeutics Market to 2018 - Market Characterization and Forecast | 31 | 14 |
| Introduction | 31 | 1 |
| Revenue Forecast | 32 | 1 |
| Market Share by Drug Class (%), 2011 | 33 | 1 |
| Branded Versus Generics Market Share (%), 2011 | 34 | 1 |
| Market Share by Company (%), 2011 | 35 | 1 |
| Annual Cost of Therapy | 36 | 2 |
| Treatment Usage Pattern | 38 | 1 |
| Diseased Population | 39 | 1 |
| Diagnosed Population | 39 | 1 |
| Prescription Population | 39 | 1 |
| HIV/AIDS Therapeutics Market - Drivers and Restraints | 40 | 1 |
| HIV/AIDS Therapeutics Market - Drivers | 40 | 1 |
| Increase in HIV Screening | 40 | 1 |
| Ryan White HIV/ AIDS Program in the US | 40 | 1 |
| High Unmet Needs | 41 | 1 |
| Amendments in Treatment Guidelines | 41 | 1 |
| Market Restraints | 42 | 1 |
| Social Stigma and Denial | 42 | 1 |
| Access to Care and Drop-outs from Treatment | 42 | 1 |
| Patent Expiries of Major Marketed Drugs | 43 | 2 |
| HIV/AIDS Therapeutics Market to 2018 - The US | 45 | 4 |
| Market Overview | 45 | 1 |
| Revenue Forecast | 45 | 1 |
| Annual Cost of Therapy | 46 | 1 |
| Treatment Usage Pattern | 47 | 1 |
| Diseased Population | 48 | 1 |
| Diagnosed Population | 48 | 1 |
| Prescription Population | 48 | 1 |
| HIV/AIDS Therapeutics Market to 2018 - Top Five European Countries | 49 | 5 |
| Market Overview | 49 | 1 |
| Revenue Forecast: Top Five European Countries | 49 | 1 |
| Revenue by Geographical Segmentation | 50 | 1 |
| Annual Cost of Therapy | 51 | 1 |
| Treatment Usage Pattern | 52 | 1 |
| Diseased Population | 53 | 1 |
| Diagnosed Population | 53 | 1 |
| Prescription Population | 53 | 1 |
| HIV/AIDS Therapeutics Market to 2018 - Japan | 54 | 4 |
| Market Overview | 54 | 1 |
| Revenue Forecast | 54 | 1 |
| Annual Cost of Therapy | 55 | 1 |
| Treatment Usage Pattern | 56 | 1 |
| Diseased Population | 57 | 1 |
| Diagnosed Population | 57 | 1 |
| Prescription Population | 57 | 1 |
| HIV/AIDS Therapeutics Market to 2018 - Emerging Markets | 58 | 12 |
| China | 58 | 1 |
| Epidemiology | 58 | 1 |
| Important Events in China s HIV/AIDS Policy Development | 59 | 1 |
| Clinical Trials in China | 60 | 1 |
| India | 61 | 1 |
| Overview | 61 | 2 |
| National AIDS Control Programs | 63 | 1 |
| Treatment Guidelines | 64 | 1 |
| Trade Related Aspects of Intellectual Property Rights Agreement and its Impact on Generics | 65 | 1 |
| Recent Developments in HIV/AIDS Therapeutics Market in India | 65 | 1 |
| Australia | 66 | 1 |
| Overview | 66 | 1 |
| Highly Specialized Drugs (Section 100) Program | 67 | 3 |
| HIV/AIDS Therapeutics Market to 2018 - Pipeline Analysis | 70 | 8 |
| Overview | 70 | 1 |
| Promising Molecules in Late Stages of Clinical Development | 71 | 1 |
| Stribild (Quad) | 71 | 1 |
| Overview | 71 | 1 |
| Efficacy | 72 | 1 |
| Safety | 72 | 1 |
| Clinical Study Details | 72 | 1 |
| Cobicistat | 73 | 1 |
| Overview | 73 | 1 |
| Efficacy | 73 | 1 |
| Safety | 73 | 1 |
| Clinical Study Details | 73 | 1 |
| JTK-303 | 74 | 1 |
| Overview | 74 | 1 |
| Efficacy | 74 | 1 |
| Safety | 74 | 1 |
| Clinical Study Details | 74 | 1 |
| 1349572 | 75 | 1 |
| Overview | 75 | 1 |
| Efficacy | 75 | 1 |
| Safety | 75 | 1 |
| Clinical Study Details | 76 | 1 |
| 572-Trii | 76 | 1 |
| Overview | 76 | 1 |
| Efficacy | 76 | 1 |
| Safety | 77 | 1 |
| Clinical Study Details | 77 | 1 |
| HIV/AIDS Therapeutics Market to 2018 - Competitive Landscape | 78 | 9 |
| Introduction | 78 | 1 |
| Major Company Profiles | 79 | 1 |
| Gilead Sciences, Inc | 79 | 1 |
| SWOT Analysis | 79 | 1 |
| GlaxoSmithKline (GSK) | 80 | 1 |
| ViiV Healthcare | 80 | 1 |
| SWOT Analysis | 81 | 1 |
| BMS | 82 | 1 |
| SWOT Analysis | 82 | 1 |
| Abbott Laboratories | 83 | 1 |
| SWOT Analysis | 83 | 1 |
| Merck | 84 | 1 |
| SWOT Analysis | 84 | 1 |
| Johnson &Johnson (J&J) | 85 | 1 |
| SWOT Analysis | 85 | 1 |
| Roche | 86 | 1 |
| HIV/AIDS Therapeutics Market to 2018 - Strategic Consolidations | 87 | 14 |
| Deals by Year | 87 | 1 |
| Deals by Type | 88 | 9 |
| Deals by Value | 97 | 1 |
| Deals by Geography | 98 | 1 |
| Summary of Major M&A Deals | 99 | 1 |
| Daiichi Sankyo Acquires Majority Stake in Ranbaxy Labs | 99 | 1 |
| Endo Pharma Acquires Indevus Pharma | 99 | 1 |
| Summary of Major Licensing Deals | 99 | 1 |
| GlaxoSmithKline Enters into Licensing Agreement with Idenix Pharma | 99 | 1 |
| BMS Enters into Licensing Agreement with Oncolys BioPharma | 99 | 1 |
| Summary of Major Partnerships | 100 | 1 |
| GlaxoSmithKline Enters into an Agreement with Concert Pharma | 100 | 1 |
| Chemrar Enters into Joint Venture Agreement with Rusnano | 100 | 1 |
| GenVec Enters into an Agreement with SAIC-Frederick | 100 | 1 |
| HIV/AIDS Therapeutics Market to 2018 - Appendix | 101 | 11 |
| Market Definitions | 101 | 1 |
| Abbreviations | 101 | 2 |
| Bibliography | 103 | 2 |
| Research Methodology | 105 | 2 |
| Coverage | 105 | 1 |
| Secondary Research | 106 | 1 |
| Primary Research | 106 | 1 |
| Therapeutic Landscape | 107 | 3 |
| Epidemiology-based Forecasting | 107 | 2 |
| Market Size by Geography | 109 | 1 |
| Geographical Landscape | 109 | 1 |
| Pipeline Analysis | 110 | 1 |
| Competitive Landscape | 110 | 1 |
| Expert Panel Validation | 110 | 1 |
| Contact Us | 110 | 1 |
| Disclaimer | 111 | 1 |
